Stryker (NYSE: SYK), a leading medical technology company, has completed its $4.9 billion acquisition of Inari Medical, Inc. (NASDAQ: NARI). Stryker Acquires Inari for $4.9B to expand its Thrombectomy and VTE Capabilities. This acquisition marks a pivotal expansion for Stryker into the high-growth venous thromboembolism (VTE) treatment space, bolstering its Neurovascular division and reinforcing its presence in the broader peripheral vascular market. The move aligns with Stryker’s strategy to strengthen its minimally invasive treatment portfolio while unlocking significant financial and market opportunities.
Founded in 2011, Inari Medical is a medical technology company specializing in innovative, catheter-based thrombectomy solutions for venous diseases. Headquartered in Irvine, California, Inari has revolutionized the treatment of venous thromboembolism (VTE) with its flagship products, ClotTriever and FlowTriever, which provide effective clot removal without the need for thrombolytic drugs. These advancements have driven Inari’s rapid growth, with annual revenue increasing by over 20% since 2017 and an outstanding 85% gross margin.
Inari operates in more than 30 countries, with only 7% of sales currently coming from international markets. Its expanding product pipeline includes new solutions for chronic venous disease, dialysis access management, and limb ischemia—tapping into an additional $5 billion market opportunity. The company’s strong innovation and market leadership make it a valuable addition to Stryker’s portfolio.
Stryker’s acquisition of Inari positions the company as a key player in the fast-growing mechanical thrombectomy market, a $15 billion industry with $6 billion in potential revenue in the U.S. alone. Stryker’s Expansion into Next-Gen Thrombectomy is a $4.9 Billion Move. Currently, less than 20% of VTE cases are treated with mechanical thrombectomy, presenting a massive opportunity for increased adoption. With growing awareness and advancements in treatment, demand for these solutions is expected to rise significantly.
Beyond VTE, Inari is actively developing solutions for chronic venous disease, dialysis access management, and limb ischemia, contributing to an additional $5 billion market opportunity. With Stryker’s global presence and strong distribution network, Inari’s expansion is expected to accelerate, tapping into underpenetrated international markets and reinforcing Stryker’s leadership in interventional vascular treatments.
Venous thromboembolism (VTE) affects nearly 900,000 individuals annually in the U.S., with a growing demand for advanced treatment options. Inari has been at the forefront of mechanical thrombectomy solutions, offering groundbreaking products such as ClotTriever and FlowTriever, which enable clot removal without thrombolytic drugs. Since their launch in 2017, these products have propelled Inari to consistent 20%+ annual revenue growth and an impressive 85% gross margin.
The integration of Inari into Stryker’s ecosystem is expected to yield substantial financial benefits in 2025 and beyond:
Stryker Corp’s stock has increased from $358.72 on January 2, 2025, to $368.15 as of April 3, 2025, reflecting a +2.63% year-to-date (YTD) gain.
The previously announced cash tender offer for all outstanding shares of Inari common stock at $80.00 per share, net to the seller in cash, expired on February 18, 2025. According to Equiniti Trust Company, LLC, 48,504,444 Inari shares—representing approximately 81.69% of the outstanding shares—were validly tendered and not properly withdrawn before the deadline.
Following the completion of the tender offer, Stryker finalized the acquisition of Inari on February 19, 2025, through a merger agreement. As a result, Inari became a wholly owned subsidiary of Stryker. Shares of Inari ceased trading on the Nasdaq Global Select Market before the opening of the market on February 19, 2025, marking the official conclusion of the transaction.
Want to know more about latest acquisitions? Read our latest blog on how Qualcomm acquired MovianAI from VinAI.
